Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?
about
Orexinergic neurotransmission in temperature responses to methamphetamine and stress: mathematical modeling as a data assimilation approach.Prenatal fat exposure and hypothalamic PPAR β/δ: Possible relationship to increased neurogenesis of orexigenic peptide neurons.Nucleus Accumbens Shell and mPFC but Not Insula Orexin-1 Receptors Promote Excessive Alcohol Drinking.Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.Orexin/hypocretin neuron activation is correlated with alcohol seeking and preference in a topographically specific manner.Different Molecular/Behavioral Endophenotypes in C57BL/6J Mice Predict the Impact of OX1 Receptor Blockade on Binge-Like Ethanol Intake.Orexin-1 receptor blockade suppresses compulsive-like alcohol drinking in mice.A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability.Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.Role of the Orexin/Hypocretin System in Stress-Related Psychiatric Disorders.The Role of Orexins/Hypocretins in Alcohol Use and Abuse.Orexin-1 receptor signalling in the prelimbic cortex and ventral tegmental area regulates cue-induced reinstatement of ethanol-seeking in iP rats.Nicotinic receptor blockade decreases fos immunoreactivity within orexin/hypocretin-expressing neurons of nicotine-exposed rats.Justifiability and Animal Research in Health: Can Democratisation Help Resolve Difficulties?Substance P in the anterior thalamic paraventricular nucleus: promotion of ethanol drinking in response to orexin from the hypothalamus.The hypocretin/orexin system as a target for excessive motivation in alcohol use disorders.
P2860
Q30955456-F360D45A-93A5-4B47-9ED0-D2FC54F64A1AQ36915135-52B3C276-E767-48E7-8825-2A8AE97900B6Q37215453-80E6852E-78E4-4D17-BA60-375521752D39Q38832061-D9F79B5E-3CF5-4666-BEC6-0F2068692514Q38849902-D55DF6E6-EAB8-4728-B10B-C048DB5A09E7Q42700560-06A6876C-1FDE-424E-B300-4FAC468D68B6Q42704272-E8CA5993-D139-4B8C-8E5C-A5E5200C9F97Q46514264-99684FD1-3BF9-4C88-9B8D-42E154191550Q47307899-2D8C3797-513D-4351-9AF0-153E5F99B585Q47329791-3A8821D1-E36A-4A14-8E09-EBD2B235D42AQ47371999-D760B4E1-F31F-4C25-BC19-9B153972CD0EQ47788221-D643F8CC-F8CC-450C-8209-A04C33665688Q48217405-7012B3EE-6B71-41FF-8A48-AEA27B23331BQ48587669-723AF0FE-D6EB-4B85-A3E2-39E3984203C6Q50002245-1F91A311-8A53-4FB0-B53B-F8C8DE4A2B4FQ52307485-1416EACE-F84E-4549-9317-751D9F6BAABFQ52316130-8E8B81A0-313D-4CF8-B38D-679CB57D1508
P2860
Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?
@en
type
label
Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?
@en
prefLabel
Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?
@en
P2860
P1433
P1476
Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?
@en
P2093
Robyn Mary Brown
Shaun Yon-Seng Khoo
P2860
P2888
P304
P356
10.1007/S40263-014-0179-X
P577
2014-08-01T00:00:00Z